Novacyt (ALNOV) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
28 Jul, 2025Executive summary
431 purchase transactions and 519 sale transactions executed under the liquidity contract in H1 2025.
228,730 shares bought for €135,502.67 and 195,320 shares sold for €119,989.44 during the period.
As of June 30, 2025, the liquidity account held 104,002 shares and €18,458.91 in cash.
Compared to December 31, 2024, share holdings increased from 70,592 to 104,002 and cash decreased from €33,678.48 to €18,458.91.
Significant events and developments
Shareholder approval on June 19, 2025, set a maximum buyback price of €5.00 per share, up to 10% of capital, for 18 months.
Liquidity contract with Invest Securities renewed, with annual remuneration of €10,000 and a two-year initial term.
Shares acquired may be cancelled or held as treasury shares without voting or dividend rights.
Capital allocation and financing
Liquidity contract allows Invest Securities to buy shares independently, with no direct company communication.
The contract is governed by French law and can be terminated by either party with two months' notice at the end of each period.
Latest events from Novacyt
- Revenue up 4% to £20.0m in 2025, with strong cash and growth in Instrumentation and APAC.ALNOV
H2 2025 TU21 Jan 2026 - Revenue up 209% to £10.3m, DHSC dispute resolved, and strong cash position supports growth.ALNOV
H1 202420 Jan 2026 - Revenue up 85% to £19.6m, cost synergies and cash reserves support new launches.ALNOV
H2 202424 Nov 2025 - EBITDA loss narrowed to £4.1m on £9.8m revenue, with strong growth in reproductive health.ALNOV
H1 202530 Sep 2025 - FY 2024 revenue up 85% to £19.6m, with strong Reproductive Health and cost efficiencies.ALNOV
H2 2024 TU6 Jun 2025